Nidanilimab
- Product Name
- Nidanilimab
- CAS No.
- 2171061-85-9
- Chemical Name
- Nidanilimab
- Synonyms
- CAN04;Nadunolimab;Nidanilimab;Research Grade Nadunolimab;Nadunolimab (anti-IL-1 RAcP);Research Grade Nadunolimab(DHJ63401)
- CBNumber
- CB28081151
- Formula Weight
- 0
- MOL File
- Mol file
Nidanilimab Property
- form
- Liquid
- color
- Colorless to light yellow
Nidanilimab Chemical Properties,Usage,Production
Uses
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].
in vivo
Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies[1].
| Animal Model: | Nude C57Bl/6 mice with LU2503 NSCLC PDX model[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy. |
IC 50
IL-1α; IL-1β
References
[1] Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
[2] Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. DOI:10.1007/s00262-022-03277-3
Nidanilimab Preparation Products And Raw materials
Raw materials
Preparation Products
Nidanilimab Suppliers
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 57505
- Advantage
- 58